The Latest Breaking News from Stephane Bancel

Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

The COVID-19 vaccine turned Moderna into a household name. What's next for the company?

Moderna’s CEO is defending a plan to more than quadruple the company’s COVID-19 vaccine price

Moderna CEO Stephane Bancel will face off with Sen. Bernie Sanders on Wednesday over the Covid shot. The battle could rock Moderna stock.

Startling cancer vaccine results from Moderna could drive the company's second act and usher in the next big thing in biotech. Here's what you need to know.

The long-awaited cancer vaccine revolution is getting a little closer to reality. New data from Moderna Inc. and Merck & Co. suggest that after decades of failures, researchers are finally figuring out the right way to design a vaccine that can teach immune cells how to recognize and combat tumors.

Moderna unveiled promising results for its personalized cancer vaccine on Tuesday. The results sent Moderna shares soaring.

The main Covid-19 booster offers good protection for at least three months.